↗5 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$887KSold on the market
1Companies
Oct 21, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 202617:53 | Oct 19, 2026 | ELVNEnliven Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $38.48 | −6,018 | 38,000 | -14% | −$232K | ||
| Oct 21, 202617:53 | Oct 19, 2026 | ELVNEnliven Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | M · Exercise10b5-1 | $14.85 | +6,018 | 44,018 | +16% | $89K | ||
| Sep 21, 202617:23 | Sep 17, 2026 | ELVNEnliven Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $50.35 | −6,018 | 38,000 | -14% | −$303K | ||
| Sep 21, 202617:23 | Sep 17, 2026 | ELVNEnliven Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | M · Exercise10b5-1 | $14.85 | +3,982 | 44,018 | +10% | $59K | ||
| Aug 19, 202616:17 | Aug 17, 2026 | ELVNEnliven Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $58.58 | −6,018 | 40,036 | -13% | −$353K |